Kindred Biosciences, Inc.
NASDAQ: KIN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Richard Chin
- Employees
- 63
- Headquarters
- Burlingame, United States
- IPO year
- 2013
- Website
- http://www.kindredbio.com
Loading KIN…
Loading profile data…Frequently asked questions about KIN
What does Kindred Biosciences, Inc. (KIN) do?
Kindred Biosciences, Inc. is a biopharmaceutical firm dedicated to the advancement of biological therapies specifically for companion animals. The company maintains an extensive pipeline of innovative biologics, spanning diverse therapeutic categories, underpinned by a robust intellectual property portfolio. Key development programs include trea...
Where does KIN trade?
Kindred Biosciences, Inc. (KIN) trades on the NASDAQ Capital Market.
What sector is KIN in?
Kindred Biosciences, Inc. (KIN) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Kindred Biosciences, Inc.?
Richard Chin is the chief executive officer of Kindred Biosciences, Inc. (KIN).
Where is Kindred Biosciences, Inc. headquartered?
Kindred Biosciences, Inc. is headquartered in United States.
Does KIN pay a dividend?
Kindred Biosciences, Inc. (KIN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KIN go public?
Kindred Biosciences, Inc. (KIN) completed its initial public offering in 2013.